“How does accentrix work?”
I have been advised to take Accentrix injection by the doctor for macular degeneration. How exactly does it work?
5 Answers
OphthalmologistMacularDegeneration
Dennis Breene
Ophthalmologist
Accentrix (Ranibizumab) is a monoclonal antibody that blocks and inhibits the activity of vascular endothelial growth factor, and thus inhibits the growth of abnormal blood vessels growing underneath the retinal in so called wet macular degeneration. It can frequently aid in the suppression of such vessels through repeated injections and significantly preserve vision. It is not curative, but anti-vegf medications have become an effective tool in preserving vision in a very serious condition.
How Accentrix Solution for Injection works:
Accentrix 10 mg/ml Solution for Injection is a monoclonal antibody, used to treat several eye diseases causing vision impairment. It works by stopping abnormal blood vessel growth and leakage in the eye(s) that occur due to excess human vascular endothelial growth factor A (VEGF-A), thereby preventing vision loss.
Accentrix 10 mg/ml Solution for Injection is a monoclonal antibody, used to treat several eye diseases causing vision impairment. It works by stopping abnormal blood vessel growth and leakage in the eye(s) that occur due to excess human vascular endothelial growth factor A (VEGF-A), thereby preventing vision loss.
It shrinks or dries up abnormal leaking blood vessels (S01LA04 - ranibizumab; Belongs to the class antineovasculatisation agents)
Manufacturer
Novartis <https://www.mims.com/malaysia/company/info/novartis>
Contents:
Ranibizumab
Indications/Uses:
Neovascular (wet) age-related macular degeneration (AMD); visual impairment due to diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO) & choroidal neovascularisation (CNV).
Contraindications:
Hypersensitivity. Active or suspected ocular/periocular infections; active intraocular inflammation.
Click to view detailed Accentrix Contraindications <https://www.mims.com/malaysia/drug/info/accentrix/special-precautions?selectedTab=3Dcontraindications>
Special Precautions:
Endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment, retinal tear & iatrogenic traumatic cataract. Monitor during the wk following inj to permit early treatment if infection occurs. Monitor & manage for increase in IOP & optic nerve head perfusion. Arterial thromboembolic events following intravitreal use of VEGF inhibitors; known risk factors for stroke (i.e., history of prior stroke or transient ischemic attack); immunogenicity. Active systemic infections or concurrent eye conditions, e.g., retinal detachment or macular hole. May affect ability to drive or use machines. Use effective contraception in women of childbearing potential. Not to be used in pregnancy. Not recommended in lactation. Not recommended in children & adolescents.
Side Effects/Adverse Reactions:
Intraocular inflammation, vitritis, vitreous detachment & floaters, retinal & conjunctival hemorrhage, visual disturbance, eye pain, irritation & pruritus; foreign body sensation in eyes, increased lacrimation & IOP, blepharitis, dry eye, ocular hyperemia, nasopharyngitis, headache, arthralgia. Retinal degeneration, disorder, detachment & tear; retinal pigment epithelium detachment & tear, reduced visual acuity, vitreous hemorrhage & disorder, uveitis, iritis, iridocyclitis, cataract, cataract subcapsular, posterior capsule opacification, punctuate keratitis, corneal abrasion, anterior chamber flare, blurred vision, inj site & eye hemorrhage, conjunctivitis, allergic conjunctivitis, eye discharge, photopsia, photophobia, ocular discomfort, eyelid edema & pain, conjunctival hyperemia, stroke, influenza, UTI, anemia, anxiety, cough, nausea, allergic reactions.
Mechanism of Action:
S01LA04 - ranibizumab; Belongs to the class antineovasculatisation agents. Used in the management of neovascular macular degeneration.
Manufacturer
Novartis <https://www.mims.com/malaysia/company/info/novartis>
Contents:
Ranibizumab
Indications/Uses:
Neovascular (wet) age-related macular degeneration (AMD); visual impairment due to diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO) & choroidal neovascularisation (CNV).
Contraindications:
Hypersensitivity. Active or suspected ocular/periocular infections; active intraocular inflammation.
Click to view detailed Accentrix Contraindications <https://www.mims.com/malaysia/drug/info/accentrix/special-precautions?selectedTab=3Dcontraindications>
Special Precautions:
Endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment, retinal tear & iatrogenic traumatic cataract. Monitor during the wk following inj to permit early treatment if infection occurs. Monitor & manage for increase in IOP & optic nerve head perfusion. Arterial thromboembolic events following intravitreal use of VEGF inhibitors; known risk factors for stroke (i.e., history of prior stroke or transient ischemic attack); immunogenicity. Active systemic infections or concurrent eye conditions, e.g., retinal detachment or macular hole. May affect ability to drive or use machines. Use effective contraception in women of childbearing potential. Not to be used in pregnancy. Not recommended in lactation. Not recommended in children & adolescents.
Side Effects/Adverse Reactions:
Intraocular inflammation, vitritis, vitreous detachment & floaters, retinal & conjunctival hemorrhage, visual disturbance, eye pain, irritation & pruritus; foreign body sensation in eyes, increased lacrimation & IOP, blepharitis, dry eye, ocular hyperemia, nasopharyngitis, headache, arthralgia. Retinal degeneration, disorder, detachment & tear; retinal pigment epithelium detachment & tear, reduced visual acuity, vitreous hemorrhage & disorder, uveitis, iritis, iridocyclitis, cataract, cataract subcapsular, posterior capsule opacification, punctuate keratitis, corneal abrasion, anterior chamber flare, blurred vision, inj site & eye hemorrhage, conjunctivitis, allergic conjunctivitis, eye discharge, photopsia, photophobia, ocular discomfort, eyelid edema & pain, conjunctival hyperemia, stroke, influenza, UTI, anemia, anxiety, cough, nausea, allergic reactions.
Mechanism of Action:
S01LA04 - ranibizumab; Belongs to the class antineovasculatisation agents. Used in the management of neovascular macular degeneration.
Accentrix is one of a class of agents that are called VEGF inhibitors. When circulation is compromised at or near the macula, it sends out a signal that stimulates the growth of new, but seriously abnormal vessels likely to lead and bleed. Accentrix will block this signal and cause atrophy of the abnormal vessels and limits the damaging effects caused by those vessels.
I advise using proper approved injections like lucentis or eylea. These drugs control macula degeneration but need regular topping up injection every month for several years. Regular monitoring is required. There are risks with these injections. Talk to your eye doctor.
